Analysis of pooled real-world data from Germany, Italy, and the United States of rVIII-SingleChain compared with standard- and long-acting FVIII products for prophylaxis of hemophilia A

Martin Olivieria Pediatric Thrombosis and Hemostasis Unit, Pediatric Hemophilia Center, Dr. von Hauner Children’s Hospital, LMU Munich, Munich, Germany

Mindy Simpsonb Rush Hemophilia and Thrombophilia Center, Rush University Medical Center, Chicago, IL, USA

Songkai Yanc CSL Behring, King of Prussia, PA, USACorrespondence[email protected]

Johanna Fedorovskyd Adivo Associates, San Francisco, CA, USA

Xiang Zhangc CSL Behring, King of Prussia, PA, USA

Radovan Tomice CSL Behring, Milan, Italy

Karen Pinachyanf CSL Behring, Mechelen, Belgium

Maria Elisa Mancusog Center for Thrombosis and Hemorrhagic Diseases, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy

show all

Analysis of pooled real-world data from Germany, Italy, and the United States of rVIII-SingleChain compared with standard- and long-acting FVIII products for prophylaxis of hemophilia A

AFSTYLA_pooled_data_comparison_manuscript_draft_7_Feb_2022_Suppl.docx

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Analysis of pooled real-world data from Germany, Italy, and the United States of rVIII-SingleChain compared with standard- and long-acting FVIII products for prophylaxis of hemophilia A

AFSTYLA_pooled_data_comparison_manuscript_draft_7_Feb_2022_Suppl.docx

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date